Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease

• DOI: 10.1002/alz.14502
• Publication Date: 2025-01-14T11:41:51Z
• Authors: Joyce R. Chong; Saima Hilal; Boon Yeow Tan; Narayanaswamy Ven...; Michael Schöll; Henrik Zetterberg; Kaj Blennow; Nicholas J. Ashton; Christopher P. Chen; Mitchell K. P. Lai
• Keywords: Concomitant; Cognitive Decline; Standardized uptake value

Abstract INTRODUCTION Using an Asian cohort with high prevalence of concomitant cerebrovascular disease (CeVD), we evaluated the performance a plasma immunoassay for tau phosphorylated at threonine 217 (p‐tau217) in detecting amyloid beta positivity (Aβ+) on positron emission tomography and cognitive decline, based three‐range reference, which stratified patients into low‐, intermediate‐, high‐risk groups Aβ+. METHODS Brain status (Aβ– [ n = 142] vs Aβ+ 73]) PET scans was assessed along ALZpath p‐tau217 assay to derive reference points 90% sensitivity (lower threshold) specificity (upper threshold). RESULTS Plasma (area under curve [AUC] 0.923) outperformed routine clinical assessments (AUC 0.760–0.819; p ≤ 0.003) other biomarkers 0.817–0.834; < 0.001). The group showed significantly higher rates decline than low‐risk group. DISCUSSION Risk stratification demonstrated potential diagnostic prognostic utility CeVD. Highlights detect brain pathology studied superior compared neuroimaging measures, workup, or blood including p‐tau181, glial fibrillary protein (GFAP), Aβ Higher correlated faster shows promise as Alzheimer's (AD) biomarker diverse populations